Eli Lilly (LLY) ended the recent trading session at $757.18, demonstrating a +0.38% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.17% ...

Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of critical drugs.

Trump administration probing extent to which pharmaceutical imports may threaten national security, a likely prelude to imposing tariffs ...

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

The Trump administration acknowledges the power of business to innovate, increase productivity and help deliver broadly shared prosperity. But going all in on tariffs restrains that power by making it ...

Jim Cramer recently highlighted Eli Lilly and Company (LLY) as a standout example of corporate efficiency, praising its ability to build a factory in record time. The factory, located in Concord, ...

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...

With Trump floating tariffs on medicine, suppliers are weighing upgrades, relocation, and, for some, the exit.